Home › Funds › Tejara Capital Ltd › SPRY
Tejara Capital Ltd position in SPRY
ARS PHARMACEUTICALS INC · Health Care
Tejara Capital Ltd reported holding 589,042 shares of SPRY (ARS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$2.5M, representing 1.24% of its reported portfolio and ranking #20 among its reported holdings. Tejara Capital Ltd has disclosed SPRY holdings in 5 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Tejara Capital Ltd's SPRY position evolved
Tejara Capital Ltd first disclosed a stake in SPRY in Q3 2023 at 103,739 shares (US$392K). The position peaked in Q2 2026 at 607,039 shares, worth US$4.9M. Across 5 filings, Tejara Capital Ltd increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 589,042 shares valued at US$2.5M — a reduction of -17,997 shares quarter over quarter.. Notable position changes include a 29% trim in Q4 2023 (shares rose 86% over the following quarter), a 189% increase in Q2 2026 (shares fell 46% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 103.74K | $392.13K | New |
| Q4 2023 | 73.74K | $404.09K | Reduce |
| Q1 2026 | 210.40K | $1.69M | New |
| Q2 2026 | 607.04K | $4.86M | Add |
| Q3 2026 | 589.04K | $2.54M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SPRY and 13F data
SPRY (ARS PHARMACEUTICALS INC) is a Health Care company. 21 other funds we track also report a position in SPRY — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$87.0M), Rubric Capital Management LP (US$68.4M), ORBIMED ADVISORS LLC (US$66.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SPRY
- RA CAPITAL MANAGEMENT, L.P. 10.86M sh · $87.00M · Q2 2026
- Rubric Capital Management LP 8.54M sh · $68.41M · Q2 2026
- ORBIMED ADVISORS LLC 8.29M sh · $66.39M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 7.50M sh · $60.11M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 4.01M sh · $32.14M · Q2 2026
- Tyro Capital Management LLC 3.20M sh · $13.79M · Q3 2026
- Third Point 1.00M sh · $8.01M · Q2 2026
- Third Point LLC 1.00M sh · $8.01M · Q2 2026
More on Tejara Capital Ltd
FAQ
How long has Tejara Capital Ltd held SPRY?
Tejara Capital Ltd has disclosed SPRY holdings in 5 of the last 13 reported quarters, going back to Q3 2023.
What is Tejara Capital Ltd's current position in SPRY?
As of Q3 2026, Tejara Capital Ltd holds 589.04K shares of SPRY (ARS PHARMACEUTICALS INC), valued at $2.54M, representing 1.24% of its reported portfolio and ranking #20.
Has Tejara Capital Ltd been buying or selling SPRY?
In the latest 13F filing (Q3 2026), Tejara Capital Ltd reduced its position in SPRY. The position peaked in Q2 2026 at 607.04K shares.
Which other funds hold SPRY?
Other major institutional holders of SPRY include RA CAPITAL MANAGEMENT, L.P., Rubric Capital Management LP, ORBIMED ADVISORS LLC, among 21 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.